Lilotomab Explained

Type:	mab
Mab Type:	mab
Source:	o
Target:	CD37
Cas Number:	1453362-55-4
Cas Supplemental:	(lutetium (^177Lu) lilotomab satetraxetan)
Unii:	58I6YNR7BV
Atc Prefix:	none
Kegg:	D12125
Synonyms:	Tetulomab, HH1
Chemspiderid:	none

Lilotomab (formerly tetulomab, HH1) is a murine monoclonal antibody against CD37,^[1] a glycoprotein which is expressed on the surface of mature human B cells. It was generated at the Norwegian Radium Hospital.^[2]

As of 2016 it was under development by the Norwegian company Nordic Nanovector ASA as a radioimmunotherapeutic in which lilotomab is conjugated to the beta radiation-emitting isotope lutetium-177 by means of a linker called satetraxetan, a derivative of DOTA.^[1] This compound is called ¹⁷⁷Lu-HH1 or lutetium (¹⁷⁷Lu) lilotomab satetraxetan (trade name Betalutin).^[3] As of 2016, a phase 1/2 clinical trial in people with non-Hodgkin lymphoma was underway.^[4]

Further reading

• Repetto-Llamazares AH, Larsen RH, Mollatt C, Lassmann M, Dahle J . Biodistribution and dosimetry of (177)Lu-tetulomab, a new radioimmunoconjugate for treatment of non-Hodgkin lymphoma . Current Radiopharmaceuticals . 6 . 1 . 20–7 . March 2013 . 23256748 . 3624777 . 10.2174/1874471011306010004 .

Notes and References

1. Recommended INN List 74. WHO Drug Information. 2015. 29. 3.
2. Robak T, Robak P . Anti-CD37 antibodies for chronic lymphocytic leukemia . Expert Opinion on Biological Therapy . 14 . 5 . 651–61 . May 2014 . 24555705 . 10.1517/14712598.2014.890182 . 19987961 .
3. Web site: Lutetium (177lu) lilotomab satetraxetan - Nordic Nanovector . Adis Insight . Springer Nature Switzerland AG . 1 September 2016.
4. Web site: EudraCT Number: 2011-000033-36. EU Clinical Trials Registry. Treatment of lymphoma with targeted internal radiation therapy (Betalutin).